Search for a trial

Can tumor uptake of [18F]afatinib in NSCLC patients be quantified, and does [18F]afatinib uptake identify patients who will benefit from afatinib therapy ?

1. To define the optimal pharmacokinetic tracer model for [18F]afatinib. 2. To determine the optimal simplified measure for quantifying tumor [18F]afatinib uptake 3. To assess [18F]afatinib uptake differences between patients (1) with wild type EGFR…